Organization
National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 abstract
Abstract
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.Org: National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Internal Medicine-Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Shanxi Provincial Cancer Hospital, Taiyuan, China,